Search
01/09/2025
Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study
Giménez, E, Cadenas, IG, Piñana, JL, Albert, E, Vázquez, L, Avendaño, A, Cabrero, M, Esquirol, A, Martino, R, López-Jiménez, J, Cuesta, MA, Humala, K, Villar, S, Rovira, M, Heras, I, Zudaire, T, Arroyo, I, Zabalza, A, Aguado, B, Solano, C, Navarro, D. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Transplant Infectious Disease. 2025; 27(5)DOI:10.1111/tid.70080. PMID:40674366. IF:2.600(Q1/1D).
01/08/2025
To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy
Pinana, JL, Martino, R, Cesaro, S, Averbuch, D, Lujgman, P. To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy. CURRENT OPINION IN INFECTIOUS DISEASES. 2025; 38(4)DOI:10.1097/QCO.0000000000001120. PMID:40471062. IF:4.000(Q1/2D).
25/07/2025
Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study
Chorao, P, Avendano, A, Heras, I, Aiello, F, Micó-Cerdá, M, Bel, AA, Garcia-Gutierrez, V, Olave, MT, Gómez, MA, Espigado, I, Cuesta-Casas, MA, González-Santillana, C, Hernández-Rivas, JA, Roldán-Pérez, A, Labrador, J, Villalba, M, Vázquez, L, Vidal, CG, Martino, R, López-Jiménez, J, Cedillo, A, Solano, C, García-Cadenas, I, Piñana, JL. Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study. BMC INFECTIOUS DISEASES. 2025; 25(1)DOI:10.1186/s12879-025-11302-w. PMID:40713537. IF:3.000(Q2/4D).
22/07/2025
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Nath, K, Zhang, MJ, Bye, M, Abid, MB, Benjamin, C, Betts, B, Bhatt, NS, Bolanos, EA, Bolon, YT, Gadalla, SM, Grunwald, MR, Krem, MM, Lee, SJ, Marsh, SGE, Martino, R, Mehta, PA, Milano, F, Prestidge, T, Saultz, JN, Shaw, BE, Spellman, SR, Choe, H, Shaffer, BC. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Advances. 2025; 9(14)DOI:10.1182/bloodadvances.2024014858. PMID:40048743. IF:7.100(Q1/2D).
08/07/2025
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
Bento, L, Gutiérrez, A, Martinez, C, Verdet, MCO, Sorribes, M, Caballero, AC, Peña, M, Pérez, A, Jiménez-Ubieto, A, Medina, L, Bastos-Oreiro, M, Caldas-González, PF, Navarro, B, Salcedo, I, Abrisqueta, P, Español, I, Cornago, J, Martín-Moro, F, García, L, Gómez, P, Varela, MR, Puente, M, Zanabili, J, Zudaire, T, Zeberio, I, del Campo, R, González, L, González, P, Blázquez, C, Rovira, J, Sitges, M, Franch-Sarto, M, Cabero, A, Mussetti, A, Montoro, J, Sampol, A, Sureda, A, Caballero, D, García-Sancho, AM. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Blood Advances. 2025; 9(13)DOI:10.1182/bloodadvances.2024015415. PMID:40163764. IF:7.100(Q1/2D).
01/07/2025
SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions
Rubio, MA, Cisa-Wieczorek, S, Mozos, A, Castellet, H, Bussaglia, E, Carricondo, M, Hernández-Alvarez, MI, Sierra, J, Nomdedéu, JF. SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions. ANNALS OF HEMATOLOGY. 2025; 104(7)DOI:10.1007/s00277-025-06458-z. PMID:40613901. IF:2.400(Q2/5D).
01/07/2025
Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials
Moreno, DF, Oriol, A, de la Rubia, J, Hernández, MT, Iñigo, MB, Palomera, L, de Arriba, F, González, Y, Teruel, AI, Pardo, JL, de la Guía, AL, Sampol, A, Ríos-Tamayo, R, Sureda, A, Gutiérrez, NC, Calasanz, MJ, Ramos, MLM, Mateos, MV, San Miguel, J, Lahuerta, JJ, Bladé, J, Rosiñol, L. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Clinical Lymphoma Myeloma & Leukemia. 2025; 25(7)DOI:10.1016/j.clml.2025.01.014. PMID:39955256. IF:2.700(Q2/4D).
04/06/2025
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party
Gagelmann, N, de Witte, M, Peczynski, C, Boreland, W, Broers, AEC, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Errico, G, Bethge, W, Maertens, J, Stölzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kröger, N, Di Chio, MC, Finazzi, MC, Corral, LL, Rifón, J, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01315-8. PMID:40467580. IF:11.600(Q1/1D).